Compile Data Set for Download or QSAR
Report error Found 200 of ic50 data for complexid = 50000428
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575593(CHEMBL4878832)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575601(CHEMBL4858933)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575588(CHEMBL4854038)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575590(CHEMBL4864361)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575591(CHEMBL4850183)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575600(CHEMBL4873487)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575586(CHEMBL4848442)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575587(CHEMBL4852516)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575592(CHEMBL4860917)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575599(CHEMBL4848140)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575568(CHEMBL4870385)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575589(CHEMBL4877684)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575594(CHEMBL4856793)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575594(CHEMBL4856793)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575596(CHEMBL4848114)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
PubMedPDB3D3D Structure (crystal)
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575604(CHEMBL4873956)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575597(CHEMBL4861509)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575579(CHEMBL4847817)
Affinity DataIC50: 0.600nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575565(CHEMBL4864280)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575576(CHEMBL4874906)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575606(CHEMBL4856040)
Affinity DataIC50: 0.800nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575555(CHEMBL4878088)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
PubMedPDB3D3D Structure (crystal)
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575575(CHEMBL4870143)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM462705(US10780090, Compound I-43 | {(1R,2S,4R)-4-[(5-{[4-...)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575581(CHEMBL4860263)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575581(CHEMBL4860263)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575595(CHEMBL4849766)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM462958([(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetra...)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575605(CHEMBL4865157)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575570(CHEMBL4865787)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575571(CHEMBL4861240)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575573(CHEMBL4862322)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM462715({(1R,2S,4R)-4-[(5-{[4-(3-chlorobenzyl)-5-methyl-2-...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM462725(US10780090, Compound I-59 | {(1R,2S,4R)-4-[(5-{[4-...)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575582(CHEMBL4862248)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575582(CHEMBL4862248)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575608(CHEMBL4851718)
Affinity DataIC50: 1.60nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575569(CHEMBL4866755)
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575577(CHEMBL4860740)
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575598(CHEMBL4862587)
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575556(CHEMBL4865086)
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575574(CHEMBL4852740)
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM462748(US10780090, Compound I-82 | [(1R,2S,4R)-4-({5-[5-(...)
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575572(CHEMBL4869144)
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575560(CHEMBL4860471)
Affinity DataIC50: 2.30nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575607(CHEMBL4861656)
Affinity DataIC50: 2.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575567(CHEMBL4859486)
Affinity DataIC50: 2.90nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575602(CHEMBL4867650)
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575594(CHEMBL4856793)
Affinity DataIC50: 3nMAssay Description:Inhibition of SAE in human HCT116 cells assessed as reduction in redistribution of SUMO2/3 proteins from nucleus to cytosol incubated for 4 hrs by im...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetSUMO-activating enzyme subunit 1/2(Human)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575594(CHEMBL4856793)
Affinity DataIC50: 3nMAssay Description:Inhibition of SAE in human HCT116 cells assessed as reduction in redistribution of SUMO2/3 proteins from nucleus to cytosol incubated for 4 hrs by im...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
Displayed 1 to 50 (of 200 total ) | Next | Last >>
Jump to: